Liquidia Corporation COO and CFO to Speak at BofA Securities Health Care Conference 2024

Liquidia Corporation, a biopharmaceutical company with a focus on products for pulmonary hypertension and other uses of its PRINT® Technology, announced that Michael Kaseta, COO and CFO, will be speaking at the BofA Securities Health Care Conference 2024 in Las Vegas, Nevada on May 14, 2024. The fireside chat will begin at 5:00 p.m. PT and a webcast will be available on Liquidia’s website for investors and interested parties.

Liquidia Corporation operates through its subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. They are also working on L606, a liposomal formulation of treprostinil for use in North America. Liquidia PAH focuses on commercializing pharmaceutical products for pulmonary diseases.

Liquidia Technologies is also developing a new product called ROFUMI™ (ROFU-miRNA) inhalation powder for the treatment of chronic obstructive pulmonary disease (COPD). This innovative product is designed to target specific genes that are involved in COPD pathogenesis by delivering microRNAs directly to airway cells using PRINT® Technology.

An archived version of the presentation will be available on Liquidia’s website for at least 30 days following the event. For more information about Liquidia Corporation, you can visit their website at www.liquidia.com. For investor inquiries, you can contact Jason Adair, the Chief Business Officer